参考文献: [1] Gilbert, M. P. , & Pratley, R. E. . (2020). Glp-1 analogs and dpp-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Frontiers in Endocrinology, 11. [2] Longato, E. , Camillo, B. D. , Sparacino, G. , Tramontan, L. , & Fad...
DPP-4抑制剂类药物,具有不易诱发低血糖和增加体重、可改善胰岛β细胞功能、可口服等显著优势,近年来市场份额增长迅速。 (来源:Bae EJ. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control [published corre...
[3] Munir KM, Lamos EM. Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose[J]Expert Opin Pharmacother,2017, 18(9): 839-841. [4] Craddy P, Palin HJ, Johnson KI...
参考文献: [1] Gilbert, M. P. , & Pratley, R. E. . (2020). Glp-1 analogs and dpp-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Frontiers in Endocrinology, 11. [2] Longato, E. , Camillo, B. D. , Sparacino, G. , Tramontan, L. , & Fad...
1. Zhang C, Ye F, Wang J, et al. Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. J Med Chem. 2020; 63(13): 7108-7126. 2. Q Ren, L Ji, L Li, et al. 642 - Hsk7653, a novel biweekly DPP-...
一项刊登在影响因子7.27杂志Diabetes上题为“DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring”的研究报告中,来自重庆第三军医大学第二附属医院的科学家们发现,应用DPP-4i是治疗糖尿病患者溃疡的首选方案。
Several DPP-4 inhibitors are in clinical development. Most experience so far has been with sitagliptin (Merck; approved by the FDA) and vildagliptin (Novartis; filed). These are orally active compounds with a long duration, allowing once-daily administration. Both sitagliptin and vildagliptin ...
在小鼠中具有更强大的DPP-4抑制作用和更好的药代动力学及药效学特性。参考文献：ChenZhang. Design, Synthesis and Evaluation of a Series of Novel Super-long ActingDPP-4 Inhibitors for the Treatment of Type 2 Diabetes J.Med. Chem. 2020(DOI: 10.1021/acs.jmedchem.0c00374)
1. Bae EJ. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control [published correction appears in Arch Pharm Res. 2016 Sep;39(9):1335]. Arch Pharm Res. 2016;39(8):1114-1128. 2. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl pe...
2. C. F. Deacon. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism.2011, 13: 7–18. (来源:《国际糖尿病》编辑部) 版 权 声 明 版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站如需转载或引用本网版权所...